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Abstract 
Background: In Namibia, as in many malaria elimination settings, reactive case detection (RACD), or malaria testing 
and treatment around index cases, is a standard intervention. Reactive focal mass drug administration (rfMDA), or 
treatment without testing, and reactive focal vector control (RAVC) in the form of indoor residual spraying, are alterna-
tive or adjunctive interventions, but there are limited data regarding their community acceptability.
Methods: A parent trial aimed to compare the effectiveness of rfMDA versus RACD, RAVC versus no RAVC, and 
rfMDA + RAVC versus RACD only. To assess acceptability of these interventions, a mixed-methods study was con-
ducted using key informant interviews (KIIs) and focus group discussions (FGDs) in three rounds (pre-trial and in years 
1 and 2 of the trial), and an endline survey.
Results: In total, 17 KIIs, 49 FGDs were conducted with 449 people over three annual rounds of qualitative data 
collection. Pre-trial, community members more accurately predicted the level of community acceptability than key 
stakeholders. Throughout the trial, key participant motivators included: malaria risk perception, access to free com-
munity-based healthcare and IRS, and community education by respectful study teams. RACD or rfMDA were offered 
to 1372 and 8948 individuals in years 1 and 2, respectively, and refusal rates were low (< 2%). RAVC was offered to few 
households (n = 72) in year 1. In year 2, RAVC was offered to more households (n = 944) and refusals were < 1%. In the 
endline survey, 94.3% of 2147 respondents said they would participate in the same intervention again.
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Background
Malaria control efforts have led to declines in malaria 
transmission worldwide [1].
In Namibia, confirmed malaria cases decreased 97%, 
from over half a million in 2001 to 14,406 in 2011, corre-
sponding to a decline in annual incidence from 422 to 11 
cases per 1000 population [2]. To further target asymp-
tomatic infections, in 2012, the National Vector-borne 
Diseases Control Programme (NVDCP) began imple-
menting reactive case detection (RACD), where teams 
visit the homes of passively-identified malaria index cases 
and conduct testing and treatment among household 
members and neighbours [3–6]. However, reliance on 
conventional rapid diagnostic tests (RDTs) limits RACD’s 
effectiveness. In Namibia and other low endemic settings 
in southern Africa, RACD using RDTs only identifies 
up to one-third of infections detected by more sensitive 
molecular methods [4, 7]. The use of molecular tests to 
inform community care is impractical due to long turn-
around times and cost [8].
An alternative to RACD is reactive focal mass drug 
administration (rfMDA), or presumptively treating 
people in active malaria foci. Reactive vector control 
(RAVC), in the form of indoor residual spraying (IRS), 
targets the mosquito and reduces human-mosquito con-
tact. The effectiveness of rfMDA versus RACD, RAVC 
versus no RAVC, and rfMDA + RAVC versus RACD only, 
were compared in a two-by-two factorial design clus-
ter randomized controlled trial [9] In adjusted analyses, 
rfMDA and RAVC implemented over a one-year period 
with over 80% coverage decreased malaria incidence by 
48 and 52%, respectively, with their combination decreas-
ing incidence by 74%.
Community acceptability is critical to intervention 
uptake, coverage, and sustainability. To understand 
acceptability of RACD, rfMDA, and RAVC, the study 
examined key factors of acceptability including: commu-
nity engagement, attitudes, and  beliefs and knowledge 
about malaria and the interventions [10–17].
Methods
Study site
The study was conducted in the western Zambezi region, 
Namibia, within 11 contiguous health facility catchment 
areas with an enumerated population of 33,418. Malaria 
transmission is seasonal and primarily due to Plasmo-
dium falciparum [18]. From 2010 to 2015, annual case 
incidence was < 15/1000 population; incidence rose in 
2016, reaching its peak at 40.2/1000 in 2017 [2, 19]. Com-
munity infection prevalence measured by highly sensitive 
loop-mediated isothermal amplification was 2.2% in 2015 
[20]. Routine Namibia Ministry of Health and Social Ser-
vices (MoHSS) interventions included case management, 
RACD, and annual pre-season IRS, using dichlorodiphe-
nyltrichloroethane (DDT) on traditional structures and 
deltamethrin on modern structures, which represent a 
minority [21].
Trial context
The trial aimed to evaluate the effectiveness of reactive 
focal interventions targeting the human and/or mosquito 
reservoirs of infection using rfMDA, RAVC, and their 
combination (rfMDA + RAVC). Trial design and results 
have been reported elsewhere [18]. Briefly, 56 enumera-
tion areas (EAs) were randomized to receive rfMDA or 
RACD, with or without RAVC (Table  1). The 2 × 2 fac-
torial design enabled assessment of individual interven-
tions and their combination.
Reactive focal interventions were triggered when a 
malaria case was passively detected and confirmed by 
RDT (CareStart, AccessBio, USA) or microscopy at a 
participating health facility. If the index case resided in 
a RACD cluster, the team performed RDT-testing in the 
index case household and neighbours; if positive, they 
provided treatment with artemether-lumefantrine (AL, 
Coartem®, Novartis Pharmaceuticals, or Komefan 140®, 
Mylan Laboratories Limited) and single dose primaquine 
(Primaquine®, Remedica), per national policy. For index 
cases in rfMDA clusters, the team offered AL to the index 
case household and neighbours withoutesting. Both 
interventions aimed to reach ≥ 25 people within 500 m of 
the index case household, prioritizing those living clos-
est. In RAVC clusters, the case household and the six 
closest households were offered IRS using micro-encap-
sulated pirimiphos-methyl (Actellic® 300 CS; Syngenta).
The acceptability study occurred during 2015 (pre-
trial), 2016, and 2017 (years 1 and 2 of the trial). While 
data from 2016 were not included in the main trial analy-
sis [9], the qualitative data from both years are included 
here, as interventions did not change year to year.
Conclusions: Communities found both reactive focal interventions and their combination highly acceptable. Engag-
ing communities and centering and incorporating their perspectives and experiences during design, implementation, 
and evaluation of this community-based intervention was critical for optimizing study engagement.
Keywords: Malaria, Plasmodium falciparum, Malaria elimination, Namibia, Mass drug administration, Indoor residual 
spraying, Reactive case detection, Community acceptability, Qualitative and Mixed Methods
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Study design
This mixed-methods study included key informant inter-
views (KIIs), focus group discussions (FGDs), and an 
endline cross-sectional survey, nested within the above 
described cluster-randomized controlled trial [9, 18]. The 
qualitative assessment followed the theoretical frame-
work of acceptability of Sekhon et  al. including: burden 
(reasons for dropout), ethical consequences (reported 
adverse events), experience (user satisfaction), affective 
attitude (attitude towards intervention), opportunity 
costs (influence on adherence and participation), and 
intention (willingness to participate) [22]. Acceptability 
was measured quantitatively through refusal rates and 
reasons for refusal during trial implementation. An end-
line cross-sectional survey measured community-level 
acceptance rates and willingness to participate in future 
interventions. Participants were eligible if they were > 15 
years old, spoke Silozi (the local language) or another 
language spoken by study personnel, resided in the study 
area, and provided informed consent.
Purposive and referral sampling were used to recruit 
participants for pre-trial KIIs. Key informants (KIs) 
included community leaders, non-governmental organ-
ization  members (NGOs), and government repre-
sentatives. After individual interviews, KIs supported 
referral sampling by suggesting KIs. Participants in 
pre-trial FGDs were community members from six 
randomly chosen health facility catchment areas in the 
study area. Two to four FGDs were conducted in each 
health facility catchment area, stratified by gender and 
three age categories: youth (15–18 years), young adult 
(19–35 years), and adult (> 35 years), except for two 
mixed-gender FGDs with NGO and MoHSS staff.
For KIIs and FGDs during Year 1 and Year 2, all resi-
dents of areas where trial interventions occurred were 
eligible, including those absent during the intervention 
or who refused to participate. FGDs were segregated 
by age: in Year 1 the age categories were: youth (15–
18 years), young adult (19–35 years), and adult (> 35 
years), in Year 2 these categories were collapsed due 
to challenges finding young participants: youth (15–
25) years and adult (> 25 years). Youth FGDs were not 
segregated by gender due to a low number of available 
young males. This change was suggested and vetted by 
local staff, who were primarily young Zambezians. KIIs 
were conducted with community leaders, all of whom 
were adult males.
For the quantitative acceptability assessment, refusal 
rates were measured during trial implementation and 
willingness to participate in future interventions was 
assessed in 2017 in an endline cross-sectional survey. 
The sampling and methods of this survey have been 
described previously [9]. The survey was powered to 
detect anticipated differences in trial outcomes. In each 
of the 56 study clusters, around 25 households were 
sampled, providing a sample size of 4440 individuals. 
Those who reported participation in a community level 
intervention were asked about willingness to partici-
pate in future interventions. Data were analysed by the 
intervention to which they were randomized in 2017, 
and then restricted to individuals that reported receipt 
of a study intervention in 2017.
Table 1 2 × 2 factorial design of parent trial
*RACD (reactive case detection): administering rapid diagnostic tests to people living within a 500 m radius of an index case; treating positives with artemether-
lumefantrine and single dose primaquine
† rfMDA (reactive focal mass drug administration): presumptively treating individuals living within a 500 m radius around an index case using artemether-
lumefantrine, without testing











No RAVC A B
(no reactive focal vector control) RACD only arm rfMDA only arm
28 clusters 14 clusters 14 clusters
RAVC‡ C D
(reactive focal vector control) RACD + RAVC arm rfMDA + RAVC arm
28 clusters 14 clusters 14 clusters
Page 4 of 11Roberts et al. Malar J          (2021) 20:162 
Data collection
Pre-trial, study staff used semi-structured interview 
guides to explore malaria knowledge, risk perception, 
presumptive treatment impressions, community par-
ticipation, and adherence optimization. During Years 
1 and 2 of the trial, study staff used semi-structured 
interview guides to explore malaria and trial per-
ceptions and experiences, intervention acceptability 
compared to MoHSS-delivered RACD, and possible 
improvements. One staff member led the FGD or KII 
and another took notes and created an audio record-
ing, both of which were used to create English tran-
scripts. Quantitative data were collected during trial 
implementation and the endline survey and recorded in 
Open Data Kit (ODK version 1.23.3).
Data management and analysis
Pre-trial and Year 1 transcript data were analysed using 
NVivo (Version 11, QSR International, Melbourne) or 
Microsoft Excel (2016, Microsoft, Redmond, Wash-
ington). Year 2 transcripts were analysed in Dedoose 
(Version 8.0.35, Los Angeles, CA, USA: Sociocultural 
Research Consultants, LLC). Quantitative data col-
lected were analysed in Stata (StataCorp. 2017. Stata 
Statistical Software: Release 15. College Station, TX: 
StataCorp LLC).
Analysis of pre-trial and Year 1 KIIs and FGDs was 
conducted by two coders, one of whom was Namib-
ian, to ensure findings incorporated local context 
and knowledge. Analysis used an inductive iterative 
approach, allowing data to guide code creation. Each 
coder independently developed codes, which were 
compared and discussed to yield a unified code set. For 
year 2 data, two coders from UCSF used a deductive 
approach; a codebook was developed based on pre-trial 
and Year 1 themes to enable comparison across years. 
An inductive approach was allowed when new themes 
emerged. Coders analysed data from each data-collec-
tion phase then compared results across phases.
Refusal rates for rfMDA were compared to RACD, 
with or without RAVC. Refusal rates of RAVC with 
and without rfMDA are reported, but refusal rates for 
RAVC could not be compared to no RAVC. Refusal 
rates were measured at the individual level for rfMDA 
and RACD, and at the household level for RAVC. 
Refusal rates across arms were compared using logistic 
regression, adjusted for clustering.
Results
Enrollment for the pre-trial, year 1, and year 2 KIIs 
and FGDs totaled 17 KIIs, 47 FGDs, and 449 FGD 
participants (Table 2). In years 1 and 2, 34 FGDs were 
conducted: RACD (6), RACD and RAVC (14), rfMDA 
(5), rfMDA and RAVC (9) (Table 3).
Pre‐trial findings
Healthcare‑seeking behaviour
When asked where community members would go if 
they suspected malaria, most respondents mentioned 
public and private health facilities. Many respondents 
mentioned that elders may visit traditional healers. An 
MoHSS employee explained that a community member’s 
first response to malaria symptoms depends on health-
care access:
You look at the community that cannot afford to 
visit the hospital or the clinic because of the dis-
tance, they will probably start with the traditional 
healers, and from there that’s when they come to the 
clinics.
Despite the use of traditional medicine, a male FGD 
respondent said that “recently it is evident that the differ-
ence between traditional healers and hospital is known… 
traditional healers cannot cure malaria disease…” This 
distinction was seen consistently throughout the FGDs.
Possible barriers to participation
FGD participants believed that stigma could reduce par-
ticipation. Some feared others would perceive them or 
their family as “unclean if a family member had malaria”. 
As one adult woman described,
But the… household who were found to be having 
malaria should also agree if they want other people 
to know… the community will label such a house-
hold as being untidy and not listening to what is 
being taught…
Table 2 Numbers of Key Informant Interviews, Focus Group 
Discussions, and Focus Group Discussion participants over study 
period, stratified by informant type and age category
NGO non-governmental organizations
Pre-trial Year 1 Year 2 All years
N N N Total
Key informant interviews
 Total interviews held 6 7 4 17
Participants
Government or NGO 6 – – 6
 Community leaders – 7 4 11
Focus group discussions
 Total discussions held 15 16 18 47
 Participants 146 127 176 449
 Youth 35 24 66 125
 Adults 111 103 110 324
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Comments about uncleanliness were made based 
on the environmental management educational program, 
which  emphasized yard and household tidiness to pre-
vent malaria.
Second, multiple participants mentioned human 
immunodeficiency virus (HIV) stigma and a perceived 
association between HIV testing and malaria testing. 
According to a female FGD participant,
Some would not go for [HIV] testing because they 
are afraid they might be found to have HIV; our peo-
ple prefers to stay without knowing [un]til they see 
that they are very sick...
Participants explained that HIV tests have a similar 
appearance to malaria RDTs and community members 
could confuse the two and refuse.
Many respondents anticipated not wanting medica-
tion if they did not feel sick or had not tested positive for 
malaria. One male FGD participant stated,
It is not all right – medication is supposed to be for 
those who have been tested.
However, participants offered factors that could make 
presumptive treatment acceptable, such as sensitization. 
One man explained,
People nowadays prefer to be tested by a doctor or 
nurse before accepting malaria dosage, though oth-
ers may agree on condition that they are properly 
informed.
All but one key informant said they would encourage 
others to accept presumptive treatment. However, three 
out of five health personnel key informants said they 
would refuse presumptive treatment, despite seeing the 
value for others.
Respondents anticipated reluctance about completing 
the full course of medication, explaining that some people 
might  stop once symptoms diminished, or if symptoms 
did not subside immediately. Respondents mentioned 
that people may save medication to treat future illness, 
given limited access and distance from health facilities. 
To improve adherence, KII and FGD respondents sug-
gested education, supervision, and reminders, especially 
for the sick, elderly, and those who cannot read.
Possible barriers to IRS were explored based on previ-
ous experience with the MoHSS. One woman discussed 
why people might decline, saying “Others close their doors 
to those who spray against mosquitoes, claiming they bring 
cockroaches”. However, several participants advised the 
inclusion of IRS, as one adult shared, “Workers go to com-
munities to spray against malaria and distribut[e] mos-
quito nets [which] needs to continue as the people really 
appreciate [it]”.
Community sensitization
KIs and FGD participants suggested ways to engage the 
community for trial sensitization and ongoing engage-
ment. According to an older male FGD participant,
…when an employed person tells you, people then 
listen. Those who went to school and are working 
tend to be influential. What they say is taken seri-
ously.
Health extension workers, teachers, and nurses were 
identified to support community sensitization. Partici-
pants agreed that better understanding of interventions 
would likely lead to higher acceptance. Participants 
emphasized the necessity of involving the tribal council, 
or khuta, for community entry and sensitization.
Year 1
Motivation to participate
Participants participated to receive protection from 
malaria via testing, treatment, and/or IRS; malaria preva-
lence made them fear infection. One woman explained, 
“After seeing how much elders and kids were complaining 
of sickness was a reason enough for me to partake.” That 
interventions were free, and that community engagement 
and sensitization efforts took place before and during the 
intervention, were described as positively influencing 
participation.
Perceptions of and attitudes towards reactive focal 
interventions
Intervention reception was overwhelmingly positive. 
Community-based care, the study team’s professionalism, 
and the respect shown for participants and local tradi-
tions were reported as critical for successful implementa-
tion. One man explained,
Most people are talking here that they have never 
seen people dedicated to their work like you showed 
us, you did not mind if the people were dirty or 
clean. You have treated them all equal… it’s the 
elders and the community leaders that are praising 
the most.
Suggestions for improvement included providing addi-
tional notice before community visits, arriving earlier, 
and processing participants and houses more quickly.
Criticisms included the lack of IRS in communities not 
receiving RAVC, lack of long-lasting insecticidal nets 
(LLINs), the need to remove furniture from households 
receiving RAVC, and a desire to receive additional medi-
cal interventions like tuberculosis and HIV testing and 
treatment. FGD participants reported that a neighbour-
ing community felt jealous that they did not receive the 
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same interventions, because they had been assigned to a 
different study arm. Such feelings can spread in commu-
nities and timely awareness provided the opportunity to 
address them.
Influences on participation and adherence
When asked why they participated, participants often 
shared that they or a relative was sick, or they knew peo-
ple who had contracted malaria recently.
“I was told some people were coming to visit me the 
following day and I should prepare my house to 
get sprayed because all four of my grandkids had 
malaria.”
Here, family illness and advance notice positively influ-
enced RAVC participation. Rationale for participation 
in RACD and rfMDA were similar; participants named 
recent illness and malaria education as motivators.
When FGD participants were asked their experience 
with malaria medication, most described positive experi-
ences, such as this FGD participant:
There was no problem with the time of taking the 
prescribed dosage by the nurse, people drank or fin-
ished the medicine very well.
FGD participants reported that negative medication 
experiences did not affect participation or willingness to 
finish the medication.A few participants in three of the 
16 FGDs raised concerns about treatment without test-
ing. One FGD participant explained,
Some people were concerned, why are they giving us 
treatment? Do they think we are sick [with] malaria?
This concern was rare; most FGD participants were not 
concerned about treatment without testing and no one 
said they refused an intervention because they disliked 
the strategy.
Continued willingness to participate
When FGDs participants were asked whether they would 
be willing to participate in the same intervention in the 
future, two of 127 participants said they would not, refer-
ring to medical interventions. One rfMDA participant 
said, “At least we should be tested first and only give medi-
cations to those who are found positive.” The other, an 
RACD recipient, said he would decline because he did 
not need further intervention, “I was already tested and I 
was negative, I don’t feel any sign of malaria.”
The overwhelming majority of participants found the 
interventions acceptable. Reasons for future participa-
tion included: to protect their families, to know if they 
are sick, and medication effectiveness. Regarding RAVC, 
participants specifically referenced IRS effectiveness. 
One participant explained, “… the spraying that you did, 
that was very nice. Afteryou sprayed both flies and mos-
quito were no longer a lot and one could sleep even with-
out a mosquito net.” This visible change in mosquito 
presence was considered proof that RAVC was effective.
Year 2
Motivation to participate
In Year 2, perceived malaria risk and the convenience of 
free community-based care and IRS continued to heav-
ily influence participation. In one FGD, a woman com-
mented, “The disease is affecting us so much that is why 
we have decided to participate,” which is noteworthy 
given the malaria outbreak the year prior (in 2016). Fur-
thermore, one FGD participant remarked on the acces-
sibility of the services,
“When you go to the clinic you will pay… you will 
find queues at the clinic, but the malaria team 
would come in the village to test and treat without 
you paying anything.”.
All four community leaders interviewed (KIs) con-
firmed that people appreciated no-cost, community-
based interventions. FGD participants appreciated that 
the study teams visited twice to increase participation 
opportunities. Education by trial teams was important, 
as one participant explained, “…always the nurse would 
explain the dose and the signs of malaria to the commu-
nity; for the past six years we thought malaria is a head-
ache, so now we know the difference”.
Perceptions of and attitudes towards reactive focal 
interventions
Most participants responded positively to rfMDA, based 
on the belief that rfMDA protects people from illness.
The majority of participants preferred rfMDA when 
asked whether rfMDA or RACD was preferable, based on 
their experience with one intervention and a description 
of the other. Concerns around RACD included: blood 
being used for satanic purposes or HIV testing, and that 
non-positive individuals miss the protective benefit of 
medication. Headmen were more neutral, stating that 
their primary concern was community health and were 
pleased with all interventions.
RAVC was generally perceived as a useful tool for 
malaria prevention. Participants in study arms that did 
and did not receive RAVC expressed a desire to have 
their houses sprayed against mosquitoes. Actellic CS was 
perceived to be “stronger” and more effective than DDT 
or Deltamethrin, the insecticides used by MOHSS. How-
ever, some participants noted strong smell, coughing, dif-
ficulty breathing, and itchy eyes with Actellic CS.
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Influences on adherence and participation
Suggestions for improvement aligned with Year 1 find-
ings, where residents and headmen asked that trial 
teams time visits better, communicate in advance, and 
provide mosquito repellants or LLINs. The majority of 
non-participants said they were unavailable during the 
intervention. However, some expressed a low malaria 
risk-perception, as one person said, “[It was] my will not 
to participate because I am always exercising, so I will not 
get malaria.” As in Year 1, a few community members 
described refusing because they disagreed with presump-
tive treatment. A community leader emphasized that 
refusal was likely due to lack of knowledge about malaria 
risk.
Continued willingness to participate
All but one FGD participant expressed willingness to 
participate in the same intervention in the future. All 
community leaders said they would welcome the inter-
vention teams again. The lone dissenter, a male partici-
pant, had participated in rfMDA + RAVC and said, “At 
least we should be tested first and only give medication 
to those who are found positive.” Some participants pre-
ferred vector-based interventions over medical inter-
ventions. One woman explained, “I don’t like tablets, 
maybe [I would participate] to have my house sprayed 
only, I don’t get healed when I drink tablets.” A few other 
respondents agreed that combining medical and vector-
based approaches, or delivering vector-based approaches 
only, were important to protect all community members.
Refusal during trial implementation—years 1 and 2
RACD or rfMDA was offered to 1372 and 8994 individu-
als during years 1 and 2 of the trial, respectively. Refusal 
rates (Table  4) were low for both interventions in both 
years (< 2%), although higher for rfMDA than RACD. 
The refusal rate for RAVC was high at 13.9% in year 1. 
Refusals were due to lack of notification before arrival, 
and reluctance to move furniture at short notice. Few 
households (n = 72) were offered RAVC in year 1 due 
to staffing and transportation  limitations (9). In year 
2, when < 1% refused, more households were offered 
RAVC (n = 923) and advance notification was provided. 
RAVC could not be compared to no RAVC. RACD, 
offered at the individual level, could not be compared 
to rfMDA + RAVC, which was offered individual and 
household levels, respectively. All interventions met or 
exceeded the goal of 80% uptake among those offered 
participation.
Willingness to participate in future interventions
2147 people participated in the acceptability portion 
of a cross-sectional survey in 2017, after the trial’s con-
clusion.  2024 respondents (94.3%) said they would par-
ticipate in the same intervention again. Of RACD cluster 
respondents, 95.5% (1546/1619) said they would par-
ticipate in a future round of RACD (Table 5). The most 
common reason for accepting RACD in the future was 
to know whether they were ill. The most common reason 
for refusing RACD in the future was that they recently 
tested negative for malaria. Of rfMDA cluster residents, 
90.5% (478/528) confirmed future participation. Most 
commonly, they liked receiving free care and wanted 
to prevent and treat malaria. Those who would refuse 
rfMDA in the future were concerned about medication 
side effects. 98.7% (616/624) of RAVC cluster residents 
said they would participate again. The most common rea-
son cited for future participation was to prevent mosqui-
toes and bugs.
Of 528 participants who reported receipt of rfMDA, 
77.5% (n = 409) rated rfMDA as equally or more accept-
able than MoHSS RACD. Of 624 participants who 
reported receipt of RAVC, 97.4% (n = 608) found RAVC 
equally or more acceptable than MoHSS-delivered IRS.
Discussion
rfMDA, RAVC, and their combination were at least 
as acceptable as RACD, the standard of care. Pre-trial, 
community members predicted the level of commu-
nity acceptability more accurately than key stakehold-
ers, who were doubtful that communities would accept 
study interventions, particularly rfMDA. Throughout 
the trial, participant motivators included: malaria risk 
perception, access to free community-based healthcare 
and IRS, and community education by respectful study 
teams. According to the theoretical framework of Sek-
hon et al. to evaluate acceptability of healthcare interven-
tions, communities found the packages of interventions 
Table 4 Refusal rates for RACD versus rfMDA among participants, and for RAVC among households
Year 1 Year 2
N Refused p-value N Refused p-value
RACD 894 3 (0.34%) 0.05 4711 10 (0.21%) < 0.001
rfMDA 478 8 (1.7%) 4283 36 (0.84%)
RAVC 72 10 (13.9%) – 923 2 (0.22%) -
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highly acceptable [22]. Refusal rates were low and partici-
pant attitude was largely positive. Community members 
understood the interventions and their purpose. While 
they had suggestions, there was no indication that they 
would refuse them in the future.
Ongoing community engagement and education was 
crucial to achieve and maintain acceptance. However, 
findings suggest the need for an even stronger approach, 
as exemplified in the interpretation of environmen-
tal management guidance as meaning that homes with 
malaria cases are “unclean” [23]. Providing malaria edu-
cation during every visit ensured community under-
standing and the visits built trust between communities 
and the trial team. Nevertheless, some community mem-
bers had misconceptions about malaria transmission and 
risk, which could be addressed with robust malaria edu-
cation. Intervention teams can play a critical role in com-
municating messages and answering questions to address 
doubts; community engagement must be ongoing and 
iterative [23]. This work can be time and resource inten-
sive, but soliciting community feedback through commu-
nity meetings and ongoing community education should 
be implemented prior to the rollout of a large-scale, com-
munity-based trial or changes in the standard of care.
Pre-trial KII and FGD results informed pre-trial com-
munity sensitization, entry, and engagement strategies. 
For example, pre-trial FGDs and KIIs identified com-
munity leaders and frontline health workers as impor-
tant information sources; the study team engaged them 
as “trial champions” to educate community members 
and facilitate community entry. The prediction by KIIs 
in the pre-trial phase that medication adherence could 
be a struggle informed the degree of time and emphasis 
placed on adherence. The qualitative data collection pro-
cess served as an ongoing monitoring mechanism, both 
formally through FGDs and KIIs, and informally through 
discussions between community members and trial staff, 
enabling the team to address issues before they impacted 
enrollment or trust.
Compared to Year 1, the FGDs after Year 2 reflected a 
somewhat higher level of inquiry about the rationale and 
processes for treatment without testing. That rfMDA 
refusal rates were lower in Year 2 compared to Year 1 sug-
gests that these questions were not connected to refusals, 
however, such comments could signal early intervention 
fatigue or that intervention familiarity enabled more 
questions.
Study limitations included the 2016 and 2017 malaria 
outbreaks, which likely increased malaria awareness and 
desire for services, possibly affecting intervention accept-
ance. Intervention coverage was low in 2016, particularly 
for RAVC, which limited the assessment of this inter-
vention in Year 1. The lack of consistency in FGD age 
and gender segmentation limited group-based analysis. 
Finally, the perceptions of refusers were not captured, 
but they constituted a small proportion of the target 
population.
Strengths of the study included repeated acceptabil-
ity data collection and immediate integration of results 
into trial procedures. Strategies to improve acceptability 
Table 5 Primary reasons for willingness or unwillingness to participate in future interventions as assessed in an endline cross-sectional 
survey
Some participants provided multiple reasons
N Willing Unwilling Don’t know/
No response
RACD 1619 1546 (95.5%) 28 (1.7%) 45 (2.8%)
Reasons: Reasons:
714 (46.2%) To know whether they were ill 17 (60.7%) Tested negative for malaria recently
380 (24.6%) To know whether their children were ill 4 (14.3%) Afraid of needles
286 (18.5%) Care was free
rfMDA 528 478 (90.5%) 31 (5.9%) 19 (3.6%)
Reasons: Reasons:
153 (32.0%) It is free 26 (83.9%) Worried about medication side effects
147 (30.8%) To both prevent and treat malaria 14 (45.2%) Do not want to take medication when not ill
105 (22.0%) Like to have their children treated
RAVC 624 616 (98.7%) 7 (1.1%) 1 (0.16%)
Reasons: Reasons:
522 (84.7%) To keep mosquitoes and bugs away 2 (28.6%) No mosquitoes in area
89 (14.4%%) Structures were sprayed well during the 
previous visit
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during this trial demonstrate that focusing on commu-
nity acceptability can strengthen implementation and 
benefit targeted communities.
These findings are relevant for community-based 
implementation trials and interventions by Ministries 
of Health. High community acceptability and uptake 
are crucial for impact and sustainability. Integrating 
these findings into future programmatic and research 
approaches can facilitate community acceptability, par-
ticularly soliciting community feedback on past, planned, 
and ongoing interventions, focusing on engagement 
rather than just sensitization, providing ongoing educa-
tion, and ensuring community needs are prioritized.
Conclusions
Communities found both reactive focal interventions 
and their combination highly acceptable. Engaging com-
munities and centering and incorporating their perspec-
tives and experiences during design, implementation, 
and evaluation of this community-based intervention 
was critical for optimizing study engagement. Additional 
evidence of best practices for centering community per-
spectives and experiences in design, implementation, 
and evaluation is needed. Finally, future pre-intervention 
evaluations should be aware that community members 
may better predict community-level acceptability than 
key stakeholders.
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